产品
编 号：F758066
分子式：C24H32N6O4.xHCl
分子式：C24H32N6O4.xHCl
产品类型
规格
价格
是否有货
结构图
CAS No: 402955-58-2
产品详情
生物活性：
PF-03049423 (Compound PF-5) is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 can be used for the research of acute ischaemic stroke.
体内研究：
PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion.PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory–motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion.Animal Model:Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) model
Dosage:0.1, 1, or 10 mg/kg
Administration:Subcutaneous injection, b.i.d. for 7 days
Result:Improved functional recovery at 1 mg/kg and 10 mg/kg.
PF-03049423 (Compound PF-5) is a potent and highly selective phosphodiesterase-5A inhibitor with an IC50 of about 0.2 nM for rat and human platelet enzyme. PF-03049423 can be used for the research of acute ischaemic stroke.
体内研究：
PF-03049423 (Compound PF-5) (1-10 mg/kg; s.c.; b.i.d. for 7 days) promotes functional recovery in a rat model of severe stroke induced by permanent middle cerebral artery occlusion.PF-03049423 (1.0 mg/kg b.i.d. or 0.6 mg/kg q.d. for 7 days) improves poststroke sensory–motor behavioral outcome even when the treatment is initiated 24-72 hours after occlusion.Animal Model:Male Sprague-Dawley rats, middle cerebral artery occlusion (MCA-o) model
Dosage:0.1, 1, or 10 mg/kg
Administration:Subcutaneous injection, b.i.d. for 7 days
Result:Improved functional recovery at 1 mg/kg and 10 mg/kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备